A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

Trial Profile

A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms SYMPHONY
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 02 Nov 2016 Results of psychometric validation of Pah-Sympact (n=278) presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 02 Nov 2016 Results of validation of Pah-Sympact (n=278) presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 08 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top